Dantrolene-induced inhibition of skeletal L-type Ca 2 + current requires RyR1 expression

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Bannister, R A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; DANTROLENE; RYANODINE RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; CA(V)1.1 PROTEIN, MOUSE; CALCIUM CHANNEL BLOCKING AGENT; RYANODINE; RYANODINE RECEPTOR;

ACTION POTENTIAL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CELL CULTURE; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG EXPOSURE; EXCITABILITY; IN VITRO STUDY; INHIBITION KINETICS; MALIGNANT HYPERTHERMIA; MEMBRANE POTENTIAL; MOUSE; MYOTUBE; NONHUMAN; PATCH CLAMP; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; SODIUM CURRENT; WHOLE CELL; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; PH; TRANSGENIC MOUSE;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; DANTROLENE; GENE EXPRESSION REGULATION; HYDROGEN-ION CONCENTRATION; MICE; MICE, TRANSGENIC; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PATCH-CLAMP TECHNIQUES; RYANODINE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84874609266     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/390493     Document Type: Article

References (35)

1. Beam K. G., Bannister R. A., Looking for answers to EC coupling's persistent questions. Journal of General Physiology 2010 136 1 7 12 2-s2.0-77954346809 10.1085/jgp.201010461
2. Nakai J., Dirksen R. T., Nguyen H. T., Pessah I. N., Beam K. G., Allen P. D., Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor. Nature 1996 380 6569 72 75 2-s2.0-0029983398 10.1038/380072a0 (Pubitemid 26076239)
3. 2+ channel. Journal of General Physiology 2000 115 4 467 480 2-s2.0-0034113889 10.1085/jgp.115.4.467 (Pubitemid 30196594)
4. 2+ current and charge movements in skeletal myotubes promoted by the β -subunit of the dihydropyridine receptor in the absence of ryanodine receptor type 1. Biophysical Journal 2003 84 2 942 959 2-s2.0-0037304631 (Pubitemid 36133420)
5. Sheridan D. C., Takekura H., Franzini-Armstrong C., Beam K. G., Allen P. D., Perez C. F., Bidirectional signaling between calcium channels of skeletal muscle requires multiple direct and indirect interactions. Proceedings of the National Academy of Sciences of the United States of America 2006 103 52 19760 19765 2-s2.0-33845915503 10.1073/pnas.0609473103 (Pubitemid 46037504)
6. 2+ channels. The Journal of Biological Chemistry 1998 273 22 13403 13406 2-s2.0-0032577476 10.1074/jbc.273.22.13403 (Pubitemid 28268377)
7. Grabner M., Dirksen R. T., Suda N., Beam K. G., The II-III loop of the skeletal muscle dihydropyridine receptor is responsible for the Bi-directional coupling with the ryanodine receptor. The Journal of Biological Chemistry 1999 274 31 21913 21919 2-s2.0-0033618408 10.1074/jbc.274.31.21913 (Pubitemid 29360027)
8. Robinson R., Carpenter D., Shaw M. A., Halsall J., Hopkins P., Mutations in RYR1 in malignant hypertheraiia and central core disease. Human Mutation 2006 27 10 977 989 2-s2.0-33748997392 10.1002/humu.20356 (Pubitemid 44454050)
9. Lanner J. T., Ryanodine receptor physiology and its role in disease. Advances in Experimental Medicine and Biology 740 1 217 234
10. Monnier N., Procaccio V., Stieglitz P., Lunardi J., Malignant- hyperthermia susceptibility is associated with a mutation of the α 1-subunit of the human dihydropyridine-sensitive L-type voltage- dependent calcium-channel receptor in skeletal muscle. American Journal of Human Genetics 1997 60 6 1316 1325 2-s2.0-0030922550 (Pubitemid 27258063)
11. Carpenter D., Ringrose C., Leo V., Morris A., Robinson R. L., Halsall P. J., Hopkins P. M., Shaw M.-A., The role of CACNA1S in predisposition to malignant hyperthermia. BMC Medical Genetics 2009 10, article 104 2-s2.0-70350521074 10.1186/1471-2350-10-104
12. Pirone A., Schredelseker J., Tuluc P., Gravino E., Fortunato G., Flucher B. E., Carsana A., Salvatore F., Grabner M., Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cav α 1S- subunit. American Journal of Physiology 2010 299 6 C1345 C1354 2-s2.0-78649658370 10.1152/ajpcell.00008.2010
13. Toppin P. J., Chandy T. T., Ghanekar A., Kraeva N., Beattie W. S., Riazi S., A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. Canadian Journal of Anesthesia 2010 57 7 689 693 2-s2.0-77953285623 10.1007/s12630-010-9314-4
14. Hopkins P. M., Malignant hyperthermia: pharmacology of triggering. British Journal of Anaesthesia 2011 107 1 48 56 2-s2.0-79959433550 10.1093/bja/aer132
15. Krause T., Gerbershagen M. U., Fiege M., Weisshorn R., Wappler F., Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004 59 4 364 373 2-s2.0-1842844355 10.1111/j.1365-2044.2004.03658.x (Pubitemid 38489297)
16. Zhao X., Weisleder N., Han X., Pan Z., Parness J., Brotto M., Ma J., Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. The Journal of Biological Chemistry 2006 281 44 33477 33486 2-s2.0-33845952839 10.1074/jbc.M602306200 (Pubitemid 46036729)
17. 2+ entry in skeletal muscle with reduced calsequestrin-1 expression. Biophysical Journal 2010 99 5 1556 1564 2-s2.0-77956581087 10.1016/j.bpj.2010.06.050
18. Cherednichenko G., Ward C. W., Feng W., Cabrales E., Michaelson L., Samso M., López J. R., Allen P. D., Pessah I. N., Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Molecular Pharmacology 2008 73 4 1203 1212 2-s2.0-41149098152 10.1124/mol.107.043299 (Pubitemid 351439202)
19. 2+ entry (ECCE). Journal of General Physiology 2009 133 1 79 91 2-s2.0-60549088369 10.1085/jgp.200810105
20. 2+ entry in dysgenic and dyspedic myotubes. Channels 2009 3 4 268 273 2-s2.0-68949148703
21. Beam K. G., Franzini-Armstrong C., Functional and structural approaches to the study of excitation-contraction coupling. Methods in Cell Biology 1997 52 1 283 306 2-s2.0-0030626741 (Pubitemid 128787399)
22. Hamill O. P., Marty A., Neher E., Sakmann B., Sigworth F. J., Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Archiv 1981 391 2 85 100 2-s2.0-0019441262 (Pubitemid 11012976)
23. Pappone P. A., Voltage-clamp experiments in normal and denervated mammalian skeletal muscle fibres. Journal of Physiology 1980 306 1 377 410 2-s2.0-0018911339 (Pubitemid 10005629)
24. Paolini C., Protasi F., Franzini-Armstrong C., The relative position of RyR feet and DHPR tetrads in skeletal muscle. Journal of Molecular Biology 2004 342 1 145 153 2-s2.0-4143110231 10.1016/j.jmb.2004.07.035 (Pubitemid 39094511)
25. Szentesi P., Collet C., Sárközi S., Szegedi C., Jona I., Jacquemond V., Kovács L., Csernoch L., Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. Journal of General Physiology 2001 118 4 355 375 2-s2.0-0034775016 10.1085/jgp.118.4.355 (Pubitemid 32980000)
26. Ellis K. O., Carpenter J. F., Studies on the mechanism of action of dantrolene sodium-a skeletal muscle relaxant. Naunyn-Schmiedeberg's Archives of Pharmacology 1972 275 1 83 94 2-s2.0-0015466582 10.1007/BF00505069
27. Prosser B. L., Hernández-Ochoa E. O., Zimmer D. B., Schneider M. F., The Q γ component of intra-membrane charge movement is present in mammalian muscle fibres, but suppressed in the absence of S100A1. Journal of Physiology 2009 587 18 4523 4541 2-s2.0-70450172741 10.1113/jphysiol.2009.177238
28. Palnitkar S. S., Mickelson J. R., Louis C. F., Parness J., Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle. The Biochemical Journal 1997 326 3 847 852 2-s2.0-0030759078 (Pubitemid 27438060)
29. Parness J., Palnitkar S. S., Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. The Journal of Biological Chemistry 1995 270 31 18465 18472 2-s2.0-0029102837 10.1074/jbc.270.31.18465
30. 2+ release by direct and specific action at skeletal muscle ryanodine receptors. The Journal of Biological Chemistry 1997 272 43 26965 26971 2-s2.0-0030777358 10.1074/jbc.272.43.26965 (Pubitemid 27452649)
31. 2+ release from the sarcoplasmic reticulum of mouse skeletal muscle fibres. British Journal of Pharmacology 2001 134 4 729 736 2-s2.0-0034751589 (Pubitemid 33016143)
32. Buck E., Zimányi I., Abramson J. J., Pessah I. N., Ryanodine stabilizes multiple conformational states of the skeletal muscle calcium release channel. The Journal of Biological Chemistry 1992 267 33 23560 23567 2-s2.0-0027081874 (Pubitemid 23088155)
33. 2+ release channel from skeletal muscle sarcoplasmic reticulum. Molecular Pharmacology 1992 42 6 1049 1057 2-s2.0-0027098189 (Pubitemid 23028842)
34. 2+ release. American Journal of Physiology 1999 276 1 C128 C135 2-s2.0-0032895046 (Pubitemid 29063575)
35. 2+ channel gating in skeletal muscle. Journal of Muscle Research and Cell Motility 2009 30 5-6 217 223 2-s2.0-75749158089 10.1007/s10974-009-9190-0